Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28042331 | 0.94 | CHRM2 (0.82) | CHRM2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1290510 | 0.90 | CHRM2 (0.70) | CHRM2HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL21879604 | 0.88 | CHRM2 (0.68) | CHRM2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL10045277 | 0.88 | CHRM2 (0.90) | CHRM2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11597593 | 0.86 | CHRM2 (0.79) | CHRM2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3118575 | 0.85 | CHRM2 (0.59) | CHRM2HDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL8780888 | 0.85 | KCNH2 (0.60) | CHRM2HDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL24002152 | 0.85 | CHRM2 (0.68) | CHRM2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL10874545 | 0.83 | CHRM2 (0.76) | CHRM2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1520064 | 0.83 | CHRM2 (0.75) | CHRM2HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-06-02 | — | — | US | disclosed |
| CN-105001096-A | 4-amino-N-alkyl benzylamine preparation methood | SHENYANG RES INST CHEMICAL IND | 2015-10-28 | — | — | CN | disclosed |
| US-8946302-B2 | Selective sigma-1 receptor ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946302-B2 | Selective sigma-1 receptor ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946302-B2 | Selective sigma-1 receptor ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-8349898-B2 | Sigma-1 receptor ligands and methods of use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349898-B2 | Sigma-1 receptor ligands and methods of use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| EP-1071665-B1 | SUBSTITUTED INDOLINONES HAVING AN INHIBITING EFFECT ON KINASES AND CYCLINE/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-6545035-B1 | Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-08 | — | — | US | disclosed |
| CN-1391557-A | 6-substituted indolinones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-01-15 | — | — | CN | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
| EP-1071665-A1 | SUBSTITUTED INDOLINONES HAVING AN INHIBITING EFFECT ON KINASES AND CYCLINE/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| US-6169106-B1 | ANTITUMOUR AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-01-02 | — | — | US | disclosed |
| WO-2000073297-A1 | SUBSTITUTED INDOLINONE AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-12-07 | — | — | WO | disclosed |
| WO-1999052869-A1 | SUBSTITUTED INDOLINONES HAVING AN INHIBITING EFFECT ON KINASES AND CYCLINE/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CHRM2 1448/4885HDAC3 91/4885HDAC1 49/4885 |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | SIGMAR1, OPRL1, OPRK1 | CHRM2 167/4885HDAC3 2686/4885HDAC1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.